Research Site

Mezitli 33200

2 studies enrolling now · 2 studies all time

What they study most

Biliary Tract Cancer, Gastroesophageal Junction Adenocarcinoma, HER2-positive Gastric Cancer

Studies at this site

• Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer — Recruiting now
• A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer — Recruiting now